Sandoz, a subsidiary division of Novartis, has launched its infliximab biosimilar, Zessly, in Germany. The launch brings the number of infliximab biosimilars available in Germany to 3.
Sandoz, a subsidiary division of Novartis, recently launched its infliximab biosimilar, Zessly, in Germany. The launch brings the number of infliximab biosimilars available in Germany to 3.
In May 2018, the European Commission authorized the biosimilar for sale in the European Union (EU). Germany will be the first European market where the drug will be available for all indications of the reference product: rheumatoid arthritis (RA), adult Crohn disease, pediatric Crohn disease, adult ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
The approval was based on a review of the data that demonstrated the infliximab biosimilar was equivalent to the reference product in terms of both safety and efficacy. The data included a phase 3 confirmatory study in RA that met its primary endpoint of achieving the American College of Rheumatology’s criteria for a 20% improvement (ACR20) response at week 14.
Reference infliximab, sold as Remicade and developed by Johnson & Johnson (J&J), earned an estimated $6.3 billion globally in 2017. However, increased competition from biosimilars is starting to eat away at its market share. During an investor call earlier this year that discussed fourth quarter sales from 2017, it was announced that Remicade sales fell by 9.7% worldwide.
In the United States, Remicade faces biosimilar competition from 2 products: Celltrion and Pfizer’s Inflectra, and Samsung Bioepis and Merck’s Renflexis. In the European Unoin, J&J’s reference infliximab fights for market share from the same products, though Renflexis is marketed under the brand name Flixabi, and Inflectra is marketed under 2 names: Inflectra and Remsima.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.